TROG 08.03 (RAVES)
Title: Radiotherapy - Adjuvant Versus Early Salvage. A Phase III Multi-centre Randomised Trial Comparing Adjuvant Radiotherapy (RT) With Early Salvage RT in Patients With Positive Margins or Extraprostatic Disease Following Radical Prostatectomy.
Primary sponsor: Trans Tasman Radiation Oncology Group (TROG)
Collaborating groups: Urological Society of Australia & New Zealand (USANZ); Australian & New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Psycho-Oncology Co-operative Research Group (PoCoG)
Final Accrual: 333
Expected closed to follow-up date: December 2021
Dr Maria Pearse, Auckland Hospital, NZ
Ms Carol Fraser-Browne
Auckland Regional Cancer and Blood Service, Private Bag 92024, Auckland, New Zealand 1142
Phone: +64 9 307 4949 ext 25197
Clinical trial registration:
Case Reports Forms
TROG 08.03 RAVES Certificate of Currencly Sept 2020-Sept 2021
In the RAVES trial, the quality assurance programme will allow us to confirm that participants have understood the technical guidelines within the protocol and implemented them correctly and that the dose prescription is delivered with appropriate documentation.
The programme consists of two parts:
Each clinician that will be entering patients into the trial will be required to participate in a dry run contouring exercise before recruiting the first patient (credentialing).
For all registered patients, treatment planning data will be submitted in electronic format.
The following documents can be used to assist in completing both parts of the Quality Assurance Programme
Summary for Radiation Therapists
Section 8 of the RAVES Protocol
Guidelines for Contouring
IMRT Credentialing Requirements
The data from the quality assurance programme will be analysed separately from the main trial. You will be notified of any major discrepancies
Benchmarking CT Data Set - Patient A
Benchmarking Data Submission Form
Patient Case Review
QA Checklist - Eligibility
QA Checklist - RT Planning
QA Checklist - RT Treatment
Please refer to the TROG Publications page
Trada Y, Kneebone A, Paneghel A, Pearse M, Sidhom M, Tang C, Wiltshire K, Haworth A, Fraser-Browne C, Martin J. Optimising Radiation therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES sub-study. International Journal of Radiation Oncology Biology and Physics. 2015; 93(5): 1045-1051.
Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, Williams SG, Brown C, Delprado W, Haworth A, Joseph DJ, Martin JM, Matthews JHL, Millar JL, Sidhom M, Spry N, Tang CI, Turner S, Wiltshire KL, Woo HH, Davis ID, Lim TS, Pearse M. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020; 21 (10): 1331-1340.
Sundaresan P, Turner S, Kneebone A, Pearse M, Butow P. Evaluating the utility of a patient decision aid for potential participants of a prostate cancer trial (RAVES-TROG 08.03). Radiother Oncol. 2011; 101 (3): 521-524.
Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, Sargos P, Sydes MR, Brawley C, Brihoum M, Brown C, Chabaud S, Cook A, Forcat S, Fraser-Browne C, Latorzeff I, Parmar MKB, Tierney JF. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 2020; 396: 1422–31.
Pearse M, Fraser-Browne CL, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim T, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the RAVES trial (Radiotherapy – Adjuvant Versus Early Salvage). British Journal of Urology International. 2014; 113 (S2): 7-12.
Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH. Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early Lessons from the 08.03 RAVES Trial. Clinical Oncology. 2014; 26(6): 348-352.
Kneebone A, Fraser-Browne C, Davis ID, Duchesne G, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph, D, Lim T, Matthews J, Millar JL, Sidhom M, Spry N, Tang C, Turner S, Williams S, Wiltshire KL, Woo H, Pearse M. Prospective analysis of late toxicity from adjuvant post prostatectomy radiotherapy in the TROG 08.03 RAVES clinical trial. Abstract from Urological Society of Australia and New Zealand Annual Scientific Meeting, 2014. Brisbane, Australia.
Sproston C, Willis D, Thompson A, Kneebone A, Pearse M, Wiltshire K, Haworth A. Rants on RAVES (Radiotherapy Adjuvant Versus Early Salvage): The challenge to meet dose constraints. J Medical Imaging and Radiation Oncology Vol 53, Supplement 1, Oral abstracts O22 – Scientific Paper/oral. RANZCR/AIR/FRO/ACPSEM Combined Scientific Meeting, October 2009.
- Haworth A, Wiltshire KL, Kneebone A, Sproston C, Willis AD, Thompson A, Sidhom M, Tang C, Williams S and Pearse M. Importance of bench marking exercises in new trial protocols – the TROG 08.03 experience. European Society for Therapeutic Radiology and Oncology (ESTRO) Annual Scientific meeting. Barcelona September 2010.
- Woo H. TROG 08.03: RAVES (Radiotherapy Adjuvant Versus Early Salvage). 12th Australasian Prostate Cancer Conference, Melbourne August 2011.
- Pearse M, Kneebone A, Duchesne G, Fisher R, Fraser-Browne C, Frydenberg M, Haworth A, Jose C, Joseph J, Lim T, Matthews J, Millar J, Sidhom M, Spry N, Tang C, Turner S, Williams S, Wiltshire K, Woo H, Davis I. What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The "RAVES" phase III randomized clinical trial. J Clin Oncol. 2012; 30 (15 suppl): TPS4690.
RAVES DA (TROG 0803 substudy)
Winner – 'Innovation in Cancer Clinical Trials' Award, 2013 NSW Premier’s Awards for Outstanding Cancer Research
10 Dec 2020
An international study (BIG 3-07/TROG 07.01) shows that after breast conserving surgery, higher radiation doses to the part of the breast where the DCIS was found, in addition to radiotherapy of the whole breast, significantly reduced its risk of returning in patients with higher-risk DCIS.
15 May 2020
The diagnosis of ductal carcinoma in situ (DCIS) of the breast has increased substantially due to mammographic screening, and now accounts for 25 per cent of screen-detected breast cancer. Over 1,600 women are diagnosed with DCIS in Australia every year. However, unlike invasive breast cancer, there are limited knowledge and experience for patients and clinicians to draw on when this now common diagnosis of DCIS is made.
15 Apr 2020
Prostate cancer is one of the most common cancers amongst men, with one in six men diagnosed before their 85th birthday (Cancer Australia). In fact, in 2019 alone over 19,000 men in Australia were diagnosed with prostate cancer.
06 Apr 2020
p style="text-align: center;">_ src="/sitefiles/trogcomau/trog_team_2020.jpg" style="height: 333px; width: 500px;" />
covid-19 and the regulations around social distancing has affected an increasing number of events across australia, including the yearly gathering of radiation...
01 Apr 2020
The coronavirus health pandemic is a challenging time for us all – personally and professionally.
We know that the changes and safety precautions required as a result of the pandemic have had significant impacts on the way we operate clinical trials – those that are underway, set t...
15 Jan 2020
_ src="/sitefiles/trogcomau/fbp_0378_large.jpg" />
new research by the university of new south wales (unsw), presented at the clinical oncology society of australia’s (cosa) annual scientific meeting (asm) found that increased use of radiation therapy for prostate cancer patients c...
13 Sep 2019
trog cancer research will work with clinicians at townsville hospital, as well as other national experts, to implement a research program aimed at understanding how to best use new mri linac technology to benefit cancer patients.
09 Sep 2019
TROG Cancer Research is currently in the final year of their 2017-2019 strategic plan. On Friday 2 August 2019, we held a strategic planning meeting with key stakeholders to discuss the direction and focus for the upcoming three years. The workshop facilitated by Ms Alison Evans, Hea...
03 Sep 2019
trog cancer research are proud to announce that we have two new additions to the trog cancer research board of directors.
joining our team is professor annette haworth and denis byron.
appointed as a non-radiation oncology director, annette is an accredited medical physicist wh...